Newly-appointed CEO accepts offer to purchase options

CombiGene’s newly-appointed CEO, Jan Nilsson, accepts an offer to purchases options within the framework of the options programme which was decided upon at the annual general meeting held on 4 April 2016. Jan Nilsson purchases 60,000 options from the options programme, which is 100 per cent of the offer. In addition to the purchase from the options programme, Jan Nilsson purchases a further 60,000 options from his predecessor as CEO.

“The purchase of 120,000 options in total reflects both the strong enthu- siasm I feel at the prospect of my as- signment as CEO and my optimistic view of CombiGene’s potential”, says Jan Nilsson in a comment. 

The information in this press release is such that CombiGene AB is obliged to publish pursuant to EU’s regulation on market abuse. The information was delivered, by the chairman, Arne Ferstad, for public dissemination on the 28th November 2016.

About CombiGene AB

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. The current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace AktieTorget.

For further information:

CombiGene AB (publ)
Arne Ferstad, Chairman of the Board
Tel: +46 72 – 206 97 25

Please read MORE FROM THE COMPANY, a newsletter from CombiGene which contains general news and infor- mation that is judged not to have a significant effect on the share price. Other issues of MOREFROMTHECOMPANY and press releases are available at

CombiGene AB (publ)     Medicon Village, SE-223 81 Lund, Sweden